Romania’s pharma market gains 1.8 percent to EUR 1.9 bln on nine months

Newsroom 04/11/2013 | 15:39

The local pharmaceuticals market moved up by 1.8 percent to EUR 1.9 billion in the first nine months of the year, driven by higher sales in the first two quarters, says a new report by Cegedim, a data provider for the pharmaceuticals industry.

In the third quarter, the market fell by 1.6 percent to EUR 627.6 million, due to lower sales of prescription based medicines in pharmacies and an 8.2 percent reduction in the hospital segment.

Cegedim suggested the market lost steam due to insufficient public financing for healthcare, which in turn means that only part of the patients can benefit from adequate treatment.

“The recent results confirm the woes of the pharmaceuticals market, with the availability of many products being significantly impacted,” said Petre Craciun, general director of Cegedim Romania. He expects the market to grow by an annualized 0.7 percent (in RON) in 2014, adding the forecast for next year is impacted by the uncertainty surrounding the update of the reimbursed drugs list.

In the first nine months, prescription based medicines moved up by 1 percent to EUR 1.4 billion, while over the counter products expanded by 7.7 percent to EUR 290 million. The hospital segment, meanwhile, shrank by 0.1 percent to EUR 263 million.

Ovidiu Posirca

BR Magazine | Latest Issue

Download PDF or read online: July August 2022 Issue | Business Review Magazine

The June 2022 issue of Business Review Magazine is now available in digital format, featuring the main cover story titled “Companies Embracing Sustainability For A Better Future” Read it online
Newsroom | 02/08/2022 | 10:15

You will receive a download link for the latest issue of Business Review Magazine in PDF format, based on the completion of the form below.

I agree with the Privacy policy of
I agree with the storage and handling of my data by

Close ×

We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

Accept & continue